TABLE 3.

Registered clinical trials using CAR-Treg adoptive immunotherapy.

Trial name	Population	CAR characteristics	Clincaltrial.gov ID
STeadfast	Living donor renal transplant recipients	HLA-A2 CAR-Tregs, autologous	NCT04817774 (protocol in Schreeb et al. (2022), commented in Lamarche and Maltzman (2022))
LIBERATE	Liver transplant recipients	HLA-A2 CAR-Tregs, autologous	NCT05234190
Allogeneic CD6-CAR Tregs for the treatment of patients with chronic graft versus host disease after allogeneic hematopoietic cell transplantation	Allogenieic hematopoietic cell transplantation recipients, for the treatment of chronic graft-versus-host disease	CD6-CAR-Tregs, allogeneic (donor-derived)	NCT05993611
CAR19 Regulatory T Cells (CAR19-tTreg) in Adults With Relapsed/Refractory CD19+ B Acute Lymphocytic Leukemia	Adults with relapsed/refractory (R/R) CD19+ B Acute Lymphocytic Leukemia (B-ALL)	CAR19-Treg, allogeneic	NCT05114837